Gilead 3Q Revenues: $2.8 billion (+15%) 3Q Earnings: $785.2 million (+17%) YTD Revenues: $8.1 billion (+14%) YTD Earnings: $2.3 billion (+25%) Comments: Product sales for the quarter increased 20% in the U.S. and 5% in Europe. Antiviral product sales increased 14% to $2.3 billion driven by strong growth in the new single tablet regimen products, Stribild (+722% to $144 million) and Complera/Eviplera (+112% to $210.7 million). Cardiovascular product sales were up 25% to $250.9 million with L...